Description
Country of Origin: Lithuania
Website: YES
Phone Support: YES
General Information:
Naresun entered the fenbendazole market in late 2023, operating as a sub-company of Fenben Lab, as evidenced in our blog post. Fenben Lab has a history of missteps in establishing sub-companies, including using the same template for two or three companies and referencing Adisant UAB, the founding entity of Fenben Lab, on their website and Amazon listings. This setup appears to be crafted solely for Fenben Lab’s maximized profit strategy.
Main Concerns:
1. Fenben Lab’s sub company
One notable aspect is the identical Terms and Conditions template used on the websites for Fenzol, Naresun, and Fenben Lab, all referencing the same entities, Adisant UAB and Canchema UAB. This copy-paste approach extends to their Certificates of Analysis (COAs), where Fenzol has even mistakenly included Naresun’s email, [email protected], on its own certificates. Additionally, Fenben Lab utilizes the same COA template, adjusting only the figures and keeping the same date across documents, which raises significant questions about the authenticity and care behind their certifications.
2. Lack of Independent Testing
None of these companies—Fenzol, Naresun, or Fenben Lab—provide results from independent testing. Instead, they rely solely on self-issued certificates, with inconsistencies that point toward manipulation. This network of nearly identical companies seems created solely to maximize profit through customer manipulation and obscurity. The uniformity and repeated errors suggest a lack of genuine commitment to quality or transparency, leaving customers potentially misled.
Conclusion:
The rise of Naresun and its associated brands highlights serious concerns about transparency and authenticity. The lack of independent testing further complicates matters, leaving consumers vulnerable to misinformation. Customers need to stay informed and cautious when engaging with these brands to ensure they make well-informed decisions.
Reviews
There are no reviews yet.